33.86
price up icon3.33%   1.09
after-market アフターアワーズ: 33.85 -0.010 -0.03%
loading
前日終値:
$32.77
開ける:
$33.13
24時間の取引高:
725.60K
Relative Volume:
0.72
時価総額:
$2.66B
収益:
$1.55M
当期純損益:
$-258.76M
株価収益率:
-8.6925
EPS:
-3.8953
ネットキャッシュフロー:
$-213.66M
1週間 パフォーマンス:
+1.90%
1か月 パフォーマンス:
+9.01%
6か月 パフォーマンス:
+42.69%
1年 パフォーマンス:
+66.88%
1日の値動き範囲:
Value
$32.43
$34.20
1週間の範囲:
Value
$31.65
$34.20
52週間の値動き範囲:
Value
$17.85
$35.79

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
名前
Celldex Therapeutics Inc
Name
セクター
Healthcare (1106)
Name
電話
908-200-7500
Name
住所
53 FRONTAGE ROAD, HAMPTON
Name
職員
198
Name
次回の収益日
2026-05-14
Name
最新のSEC提出書
Name
CLDX's Discussions on Twitter

Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CLDX icon
CLDX
Celldex Therapeutics Inc
33.86 2.57B 1.55M -258.76M -213.66M -3.8953
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 109.34B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 74.35B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 50.44B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 39.78B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.02B 5.36B 287.73M 924.18M 2.5229

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-20 アップグレード Barclays Underweight → Overweight
2026-03-23 アップグレード Wolfe Research Peer Perform → Outperform
2025-10-21 開始されました Mizuho Outperform
2025-10-13 開始されました Barclays Underweight
2025-04-28 開始されました Canaccord Genuity Buy
2025-03-20 開始されました Morgan Stanley Overweight
2025-02-13 開始されました UBS Buy
2024-10-07 開始されました Citigroup Buy
2024-09-30 開始されました Goldman Neutral
2024-09-27 ダウングレード Wolfe Research Outperform → Peer Perform
2024-06-18 開始されました Stifel Buy
2024-06-11 開始されました Wolfe Research Outperform
2023-12-20 開始されました TD Cowen Outperform
2023-11-10 アップグレード Wells Fargo Underweight → Equal Weight
2023-08-22 開始されました Wells Fargo Underweight
2021-09-17 開始されました Jefferies Buy
2021-09-10 開始されました SVB Leerink Outperform
2021-07-22 開始されました Guggenheim Buy
2020-02-21 開始されました Cantor Fitzgerald Overweight
2017-08-01 再開されました H.C. Wainwright Buy
2016-11-07 開始されました Aegis Capital Buy
2016-03-08 ダウングレード Jefferies Buy → Hold
2016-03-07 ダウングレード Guggenheim Buy → Neutral
2016-03-07 ダウングレード Leerink Partners Outperform → Mkt Perform
2016-03-07 ダウングレード Wedbush Outperform → Neutral
2016-03-01 開始されました H.C. Wainwright Buy
2015-08-11 繰り返されました Brean Capital Buy
2015-08-11 繰り返されました Oppenheimer Outperform
2015-08-11 繰り返されました ROTH Capital Buy
2015-06-02 繰り返されました WBB Securities Strong Buy
2014-11-17 繰り返されました ROTH Capital Buy
2014-03-04 繰り返されました Oppenheimer Outperform
2013-07-08 繰り返されました Cantor Fitzgerald Buy
2013-03-08 繰り返されました Cantor Fitzgerald Buy
2013-02-26 繰り返されました Oppenheimer Outperform
2013-01-10 繰り返されました Cantor Fitzgerald Buy
2012-10-02 繰り返されました Oppenheimer Outperform
2012-09-14 繰り返されました Cantor Fitzgerald Buy
すべてを表示

Celldex Therapeutics Inc (CLDX) 最新ニュース

pulisher
May 04, 2026

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High? - Yahoo Finance

May 04, 2026
pulisher
May 03, 2026

MSN Money - MSN

May 03, 2026
pulisher
May 01, 2026

Pictet Asset Management Holding SA Reduces Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat

May 01, 2026
pulisher
Apr 30, 2026

Asthma Pipeline Enters a New Era of Precision Respiratory Care with 100+ Therapies and 80+ Companies Advancing Next-Generation Biologics and Small Molecules | DelveInsight - Barchart.com

Apr 30, 2026
pulisher
Apr 29, 2026

Vanguard Capital Management (NASDAQ: CLDX) reports 3.45M shares; 5.17% stake - Stock Titan

Apr 29, 2026
pulisher
Apr 29, 2026

Celldex earnings on deck as barzolvolimab Phase 3 nears readout By Investing.com - Investing.com South Africa

Apr 29, 2026
pulisher
Apr 29, 2026

Celldex earnings on deck as barzolvolimab Phase 3 nears readout - Investing.com UK

Apr 29, 2026
pulisher
Apr 29, 2026

[ARS] Celldex Therapeutics, Inc. SEC Filing - Stock Titan

Apr 29, 2026
pulisher
Apr 29, 2026

Celldex (NASDAQ: CLDX) sets 2026 virtual meeting, seeks approval for equity plan - Stock Titan

Apr 29, 2026
pulisher
Apr 29, 2026

Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN

Apr 29, 2026
pulisher
Apr 28, 2026

Celldex Therapeutics announces public offering of common stock - MSN

Apr 28, 2026
pulisher
Apr 28, 2026

Celldex Therapeutics (NASDAQ:CLDX) Shares Pass Above 200 Day Moving AverageWhat's Next? - MarketBeat

Apr 28, 2026
pulisher
Apr 25, 2026

Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump - Yahoo Finance

Apr 25, 2026
pulisher
Apr 23, 2026

Is Celldex (CLDX) stock a strategic buy | Q4 2025: EPS Misses ViewsCommunity Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 23, 2026
pulisher
Apr 23, 2026

Celldex (CLDX) Operational Review | Q4 2025: Earnings UnderperformPrice Target - Cổng thông tin điện tử tỉnh Lào Cai

Apr 23, 2026
pulisher
Apr 22, 2026

Assessing Celldex Therapeutics (CLDX) Valuation After Strong Recent Share Price Gains - simplywall.st

Apr 22, 2026
pulisher
Apr 22, 2026

Why Celldex Stock Is Suddenly Sliding Again - TipRanks

Apr 22, 2026
pulisher
Apr 21, 2026

Celldex Therapeutics Inc (CLDX) - MSN

Apr 21, 2026
pulisher
Apr 21, 2026

Barclays upgrades Celldex Therapeutics (CLDX) - MSN

Apr 21, 2026
pulisher
Apr 21, 2026

Celldex (CLDX) Stock VWAP Analysis (-0.49%) 2026-04-20AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 21, 2026
pulisher
Apr 20, 2026

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade - MarketBeat

Apr 20, 2026
pulisher
Apr 20, 2026

Barclays Upgrades Celldex Therapeutics to Overweight From Underweight, Adjusts Price Target to $45 From $24 - marketscreener.com

Apr 20, 2026
pulisher
Apr 20, 2026

Barclays upgrades Celldex stock rating on trial enrollment progress By Investing.com - Investing.com Australia

Apr 20, 2026
pulisher
Apr 20, 2026

Barclays upgrades Celldex stock rating on trial enrollment progress - Investing.com UK

Apr 20, 2026
pulisher
Apr 18, 2026

Celldex (CLDX) Stock: Performance Drivers (Modest Uptick) 2026-04-18Real Trader Network - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026
pulisher
Apr 18, 2026

Celldex Therapeutics stock hits 52-week high at 34.55 USD By Investing.com - Investing.com India

Apr 18, 2026
pulisher
Apr 17, 2026

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month HighHere's What Happened - MarketBeat

Apr 17, 2026
pulisher
Apr 17, 2026

Celldex Therapeutics stock hits 52-week high at 34.55 USD - Investing.com

Apr 17, 2026
pulisher
Apr 17, 2026

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apr 17, 2026
pulisher
Apr 15, 2026

Tudor Investment Corp ET AL Makes New $818,000 Investment in Celldex Therapeutics, Inc. $CLDX - MarketBeat

Apr 15, 2026
pulisher
Apr 15, 2026

Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment - MarketBeat

Apr 15, 2026
pulisher
Apr 14, 2026

CLDX: Barzolvolimab shows strong, durable efficacy in urticaria with pivotal phase III data due Q4 - TradingView — Track All Markets

Apr 14, 2026
pulisher
Apr 13, 2026

Celldex to Present at Upcoming Investor Conference - The Manila Times

Apr 13, 2026
pulisher
Apr 13, 2026

Celldex will stream April 14 fireside chat from skin disease event - Stock Titan

Apr 13, 2026

Celldex Therapeutics Inc (CLDX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
大文字化:     |  ボリューム (24 時間):